SCHEMBL3327016

SCHEMBL3327016

CC(C)COc1ccccc1O[C@@H](C)[C@H]1CCCNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.42
SLC6A2 P23975 10/20 0.41
SLC6A4 P31645 10/20 0.41
SLC6A3 Q01959 10/20 0.41
IKBKB O14920 1/20 0.39
HTR2C P28335 2/20 0.37
MLNR O43193 1/20 0.37
ADRB2 P07550 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
OPRK1 P41145 1/20 0.37
KCNH2 Q12809 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327020 1.00 ALOX15 (0.42) ALOX15SLC6A2SLC6A4SLC6A3IKBKB
SCHEMBL3325173 1.00 ALOX15 (0.42) ALOX15SLC6A2SLC6A4SLC6A3IKBKB
SCHEMBL3323892 0.88 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3HTR2CMLNR
SCHEMBL3325931 0.88 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3HTR2CMLNR
SCHEMBL3325927 0.88 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3HTR2CMLNR
SCHEMBL3322368 0.88 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3HTR2CMLNR
SCHEMBL3328340 0.85 SLC6A4 (0.46) SLC6A2SLC6A4SLC6A3HTR2CNISCH
SCHEMBL3321744 0.85 IRAK4 (0.41) SLC6A2SLC6A4SLC6A3IKBKBADRB2
SCHEMBL3324779 0.85 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3HTR2CMLNR
SCHEMBL3328335 0.85 SLC6A4 (0.46) SLC6A2SLC6A4SLC6A3HTR2CNISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US claimed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP claimed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO claimed
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US disclosed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP disclosed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120858-A1 Piperidine Derivatives P2RX5, P2RX7, P2RX1 ALOX15 3791/4885SLC6A2 2609/4885SLC6A4 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.